



IBS-D* DOESN'T HAVE TO
BE A CONSTANT WORRY.

THAT'S WHY THERE'S

Xifaxan[®]
rifaximin 550 mg tablets

XIFAXAN is the only FDA-approved **2 week treatment** that provided up to **6 months**[†] of relief from abdominal pain and diarrhea associated with IBS-D.

*IBS-D: irritable bowel syndrome with diarrhea.

[†]In a clinical trial: range of 6 to 24 weeks; average of 10 weeks of relief from abdominal pain and diarrhea. You can be retreated up to 2 times if symptoms return.

INDICATION

XIFAXAN[®] (rifaximin) 550 mg tablets are indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

- XIFAXAN is not for everyone. Do not take XIFAXAN if you have a known hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN.

Please see additional Important Safety Information throughout and accompanying [full Prescribing Information](#).

WHAT IS IBS-D?

IBS-D stands for irritable bowel syndrome with diarrhea. IBS-D patients often suffer from multiple symptoms. Symptoms can vary over time and often include:



ABDOMINAL PAIN

Frequent stomach discomfort resulting in distraction from what matters



DIARRHEA

Loose, mushy, or watery stools and/or frequent bowel movements



BLOATING

Abdominal discomfort due to excessive intestinal gases



URGENCY

The unpleasant sensation to rush to the toilet to have a bowel movement

WHAT CAUSES IBS-D?

The exact cause of IBS-D is unknown, though various factors can play a role in creating symptoms. Your gut normally contains many types of bacteria that help digest the food you eat and keep you healthy.



A range of evidence suggests an imbalance in these bacteria may lead to symptoms of IBS-D.

You are not alone

IBS is a common disorder of the large intestine (colon) that affects up to

12 MILLION AMERICANS

Are there other causes?

There are many factors that may cause IBS-D symptoms, such as:

- Food sensitivity
- Inflammation in the intestines
- Abnormal intestinal contractions or spasms
- Improper signals between the brain and the intestines

HOW DOES XIFAXAN WORK IN IBS-D?

XIFAXAN is believed to affect an underlying factor of IBS-D by directly attacking bacteria in the gut that may be linked to IBS-D symptoms.



XIFAXAN is the only FDA-approved treatment for IBS-D that alters bacteria in the gut.

Only your healthcare provider can tell if your symptoms are caused by IBS-D and if XIFAXAN may be right for you.

ACG Recommendation

The American College of Gastroenterology (ACG), a leading authority in GI disorders, has given XIFAXAN (rifaximin) a strong recommendation to treat global IBS-D symptoms. This is based on a moderate level of clinical trial data.



If you want to learn more about the clinical data supporting the recommendation to see if XIFAXAN is right for you, talk to your doctor.

IMPORTANT SAFETY INFORMATION (continued)

- If you take antibiotics, like XIFAXAN, there is a chance you could experience diarrhea caused by an overgrowth of bacteria (*C. difficile*). This can cause symptoms ranging in severity from mild diarrhea to life-threatening colitis. Contact your healthcare provider if your diarrhea does not improve or worsens.

Please see additional Important Safety Information throughout and accompanying [full Prescribing Information](#).

HOW TO TAKE XIFAXAN



XIFAXAN is a short-term treatment that you take 3 times a day for 2 weeks.

You can be retreated up to 2 times if symptoms return.

Convenient dosing that provided significant relief:

- Take one XIFAXAN 550 mg tablet 3 times a day for 2 weeks[§]
- You can take with or without food
- Be sure to complete the entire 2-week course of treatment, even if you begin to feel better before you have finished
- You can be retreated up to 2 times if symptoms come back

[§]Always take XIFAXAN as directed by your healthcare provider.



Patients are finding relief,
watch their stories at
[Xifaxan.com](https://www.xifaxan.com)

IMPORTANT SAFETY INFORMATION (continued)

- Talk to your healthcare provider before taking XIFAXAN if you have severe hepatic (liver) impairment, as this may cause increased effects of the medicine.

Please see additional Important Safety Information throughout and accompanying [full Prescribing Information](#).

MOST COMMON SIDE EFFECTS

HOW XIFAXAN CAN HELP TREAT YOUR IBS-D

Xifaxan
rifaximin 550 mg tablets

Patients taking XIFAXAN had similar rates of side effects to those taking placebo.

In clinical studies, the most common side effects with XIFAXAN for IBS-D were:

- Nausea (feeling sick to your stomach)[†]
- An increase in liver enzymes[‡]

Constipation was observed in only 0.5% of XIFAXAN patients.

[†]Nausea was observed in 3% of patients taking XIFAXAN vs 2% taking placebo.
[‡]Liver enzymes increase observed in 2% of patients taking XIFAXAN vs 1% taking placebo.

XIFAXAN has a well-established Safety Profile.

- **NOT** a controlled substance
- **NOT** contraindicated in patients without a gallbladder
- **No association** of pancreatitis was observed in patients taking XIFAXAN in the clinical trials

2 week treatment
UP TO **6** months of relief[†]

[†]In a clinical trial: range of 6 to 24 weeks; average of 10 weeks of relief from abdominal pain and diarrhea. You can be retreated up to 2 times if symptoms return.

IMPORTANT SAFETY INFORMATION (continued)

- Tell your healthcare provider if you are taking drugs called P-glycoprotein and/or OATPs inhibitors (such as cyclosporine) because using these drugs with XIFAXAN may lead to an increase in the amount of XIFAXAN absorbed by your body.
- In clinical studies, the most common side effects of XIFAXAN in IBS-D were nausea (feeling sick to your stomach) and an increase in liver enzymes.

Please see additional Important Safety Information throughout and accompanying [full Prescribing Information](#).

XIFAXAN is a 2-week treatment that provided up to 6 months of relief from abdominal pain and diarrhea, associated with IBS-D in a clinical trial.^{†‡}



[†]In a clinical trial: range of 6 to 24 weeks; average of 10 weeks of relief from abdominal pain and diarrhea.

[‡]You can be retreated up to two times if symptoms come back.

Returning symptoms, when reported, were less severe after treatment with XIFAXAN. If your symptoms come back, talk to your doctor about retreatment.

In additional clinical studies, XIFAXAN provided significant relief of IBS-related bloating and urgency.

The number of bowel movements per day was also studied, but there was no significant difference between XIFAXAN and placebo (sugar pill).

IMPORTANT SAFETY INFORMATION (continued)

- XIFAXAN may affect warfarin activity when taken together. Tell your healthcare provider if you are taking warfarin because the dose of warfarin may need to be adjusted to maintain proper blood-thinning effect.
- If you are pregnant, planning to become pregnant, or nursing, talk to your healthcare provider before taking XIFAXAN because XIFAXAN may cause harm to an unborn baby or nursing infant.

Please see additional Important Safety Information throughout and accompanying [full Prescribing Information](#).

XIFAXAN has the best insurance coverage of any medication approved for adults with IBS-D.^{||}



90% of eligible,[#] commercially insured patients who had coverage for XIFAXAN paid \$10 or less for their prescription when a copay card or eVoucher was applied in 2020.^{||}

^{||}98% of commercially insured patients and 96% of Medicare patients have coverage for XIFAXAN.

[†]Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full cash-paying patients. This offer may not be redeemed for cash. By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described herein and will not seek reimbursement for any benefit received through this card. This offer is only good in the USA at participating retail pharmacies. This offer cannot be redeemed at other locations, including government-subsidized clinics or facilities. This offer is not valid where otherwise prohibited, taxes, or otherwise restricted. Patient is responsible for reporting receipt of co-pay assistance to any insurer, healthcare plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. This offer cannot be combined with other offers. This offer is nontransferable. No substitutions are permitted. Salix Pharmaceuticals reserves the right to rescind, revoke, or amend this offer at any time without notice. This offer expires on December 31, 2021. Visit xifaxan.com or call 1-855-250-3759 for full eligibility criteria, terms and conditions.

[#]Data on file. Salix Pharmaceuticals. Bridgewater, NJ.

Download or activate at
Xifaxan.copaysavingsprogram.com



IMPORTANT SAFETY INFORMATION (continued)

XIFAXAN is not for everyone. Do not take XIFAXAN if you have a known hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch/ or call 1-800-FDA-1088.

For product information, adverse event reports, and product complaint reports, please contact:

Salix Product Information Call Center
Phone: 1-800-321-4576 | Fax: 1-510-595-8183
Email: salixmc@dlss.com

Please see additional Important Safety Information throughout and accompanying [full Prescribing Information](#).

Salix Pharmaceuticals
400 Somerset Corporate Blvd., Bridgewater, NJ 08807



The XIFAXAN 550 mg product and the XIFAXAN trademark are licensed by Alfasigma S.p.A. to Salix Pharmaceuticals or its affiliates.
© 2021 Salix Pharmaceuticals or its affiliates. XIF1.0042.USA.20 v2.0